✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Cohance Lifesciences Ltd.

COHANCE

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹37,507 Cr.
P/E
140.02

Cohance Lifesciences Ltd.

  • Cohance Lifesciences
  • Jubilant Pharmova
  • Syngene Internation.
  • TJI Pharma - API & CRAMS
FAQs on Cohance Lifesciences Ltd. Shareprice

Cohance Lifesciences has given better returns compared to its competitors.
Cohance Lifesciences has grown at ~41.5% over the last 2yrs while peers have grown at a median rate of 26.41%

Yes, Cohance Lifesciences is expensive.
Latest PE of Cohance Lifesciences is 140, while 3 year average PE is 54.61.
Also latest EV/EBITDA of Cohance Lifesciences is 101 while 3yr average is 41.63.

View FAQ's On Business
Growth Table
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Balance Sheet
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Cash Flow
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Quarterly Results
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Cohance Lifesciences Ltd. Financials

Balance sheet of Cohance Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Cohance Lifesciences is increasing.
Latest net debt of Cohance Lifesciences is -₹10.54 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹62.36 Crs.

No, profit is decreasing.
The profit of Cohance Lifesciences is ₹265 Crs for TTM, ₹300 Crs for Mar 2024 and ₹411 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Cohance Lifesciences latest dividend payout ratio is 37.14% and 3yr average dividend payout ratio is 32.59%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech